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Abstract 
Background: Heart failure with ejection fraction (HFpEF) is a syndrome resulting from several co‑morbidities in 
which specific mediators are unknown. The platelet proteome responds to disease processes. We hypothesize that 
the platelet proteome will change composition in patients with HFpEF and may uncover mediators of the syndrome.
Methods and results: Proteomic changes were assessed in platelets from hospitalized subjects with symptoms of 
HFpEF (n = 9), the same subjects several weeks later without symptoms (n = 7) and control subjects (n = 8). Mass 
spectrometry identified 6102 proteins with five scans with peptide probabilities of ≥0.85. Of the 6102 proteins, 165 
were present only in symptomatic subjects, 78 were only found in outpatient subjects and 157 proteins were unique 
to the control group. The S100A8 protein was identified consistently in HFpEF samples when compared with controls. 
We validated the fining that plasma S100A8 levels are increased in subjects with HFpEF (654 ± 391) compared to 
controls (352 ± 204) in an external cohort (p = 0.002). Recombinant S100A8 had direct effects on the electrophysi‑
ological and calcium handling profile in human induced pluripotent stem cell‑derived cardiomyocytes.
Conclusions: Platelets may harbor proteins associated with HFpEF. S100A8 is present in the platelets of subjects with 
HFpEF and increased in the plasma of the same subjects. We further established a bedside‑to‑bench translational 
system that can be utilized as a secondary screen to ascertain whether the biomarkers may be an associated finding 
or causal to the disease process. S100A8 has been linked with other cardiovascular disease such as atherosclerosis and 
risk for myocardial infarction, stroke, or death. This is the first report on association of S100A8 with HFpEF.
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Background
The platelet proteome is an untapped resource for identi-
fying proteins that may reflect a disease process. Platelets 
are easily accessible and free from major highly abundant 
proteins making them an attractive model for proteomic 
studies. Platelets change the composition of their pro-
teins in diseases such as Alzheimer’s, cancer, diabetes, 
coronary artery disease and acute coronary syndrome 
[1–4]. Platelets are largely under-studied in heart failure, 
yet evidence indicates that both platelet function [5, 6] 
and platelet-derived proteins such as adhesion molecules 
and the natriuretic peptide receptor-C [7–10] are altered 
in heart failure. Therefore, changes in the platelet pro-
teome may allow for the identification of proteins that 
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Heart failure with preserved ejection fraction (HFpEF) 
affects almost 50  % of patients with heart failure and is 
increasing in prevalence [11], yet the pathophysiological 
mechanisms are poorly understood. HFpEF is associ-
ated with diabetes, hypertension, renal dysfunction, atrial 
fibrillation and obesity. The systemic inflammatory state 
induced by these co-morbidities is predictive of HFpEF 
[12, 13]. Platelets are both contributors and respond-
ers of inflammatory processes [14]. Considering there 
are no targeted therapies for HFpEF and morbidity and 
mortality are high, it is paramount to identify biomark-
ers associated with HFpEF and clarify their mechanistic 
role in clinical heart failure in order to develop targeted 
treatments. Consequently, by examining the platelet pro-
teome of subjects with HFpEF, there is the potential to 
identify proteins that may provide insight into the disease 
mechanisms.
We established a novel bed-to-bench translational sys-
tem to identify potential mediators of HFpEF using both 
platelet proteome analysis and mechanistic studies in 
induced pluripotent stem cell-derived cardiomyocytes. 
The broad utility of this strategy is to incorporate bioac-
tivity studies into guiding the selection of proteins from 
proteomic studies for further investigation. We sought 
to compare the platelet proteome among subjects with 
HFpEF in the uncompensated (hospitalized) state, com-
pensated (outpatient) state, and controls combined with 
validation in plasma samples from an external cohort 
and bioactivity studies using human induced pluripotent 
stem cell (iPSC)-derived cardiomyocytes. We hypoth-
esized that [1] platelet proteomic analysis would suc-
cessfully identify a protein associated with HFpEF, and 
[2] human iPSC-derived cardiomyocytes treated with 
recombinant proteins could serve as further validation by 
demonstrating phenotypic changes in cardiomyocyte cal-
cium handling, which is altered in HFpEF.
Methods
Study population
For the discovery phase, subjects ≥50 years old present-
ing with New York Heart Association class II–III heart 
failure symptoms, a left ventricular ejection fraction 
(LVEF) >50  %, echocardiographic evidence of diastolic 
dysfunction and increased LV filling pressure were evalu-
ated at the Medical College of Wisconsin between June 
2012 to December 2013 for participation in this study. 
Increased LV filling pressures were defined as E/e′ ≥ 15, 
or E/e′ ≥ 8 and ≤ 15 with either a BNP ≥ 200 pg/ml or 
a left atrial (LA) volume index > 40 ml/m2. Subjects were 
excluded if they had a clinical condition that potentially 
changed the platelet or plasma proteomic profile inde-
pendent of HFpEF such as uncontrolled diabetes, an 
active infection or inflammatory disorder, chronic renal 
failure requiring dialysis, severe liver disease, malig-
nancy, acute myocardial infarction, chronic obstructive 
pulmonary disease requiring steroids, or recent surgical 
or invasive cardiac procedures. Subjects were excluded 
if they had other cardiac causes for their symptoms such 
as severe valvular disease, amyloidosis, or hypertrophic 
cardiomyopathy. Blood was drawn from the nine sub-
jects enrolled in the study (HFpEF hospitalized group). 
Five of these subjects (HFpEF outpatient group) returned 
≥2 weeks after discharge for second blood draw. Subjects 
with an LVEF ≥50 % and without evidence of increased 
LV filling pressures served as the control group.
For further biomarker validation, an additional set of 
25 HFpEF subjects and 18 age and co-morbidity matched 
control subjects were recruited from Northwestern Uni-
versity. All subjects gave written informed consent to 
participate in the study. The Institutional Review Board 
at the Medical College of Wisconsin and Northwest-
ern University approved the respective study protocols, 
which conformed to the principles of the Declaration of 
Helsinki.
Reagents
Supplies and other reagents were purchased from Sigma-
Aldrich (St. Louis, MO) unless specified. Recombinant 
S100A8 was purchased from Creative BioMart (Shirley, 
NY).
Platelet preparation
Blood was separated into serum and platelet fractions. 
Platelets were extensively washed in buffer (45  mM 
sodium citrate, 25  mM citric acid, 80  mM d-glucose). 
During all steps, care was taken to avoid activation of 
platelets. Flow cytometry with anti-CD41 (Life Technol-
ogies, Grand Island, NY) and anti-P-selectin (BioLegend, 
San Diego, CA) was performed to assess for platelet acti-
vation (Additional file: 1. Figure S1). Microscopy confir-
mation verified that the purified platelets had leukocyte 
and red blood cell contamination that was less than 0.02 
and 1 %, respectively (Additional file: 2. Figure S2).
Global proteomic studies
Platelets from individual samples were resuspended in 
lysis buffer (125  mM Tris pH 6.8, 4  % SDS, 10  % glyc-
erol, 5  % β-mercaptoethanol, Roche Complete Pro-
tease Inhibitor, Thermo HALT Phosphatase Inhibitor 
Cocktail). After determining protein concentration, the 
protein sample was separated by 1-dimensional SDS-
PAGE gel (Bis-Tris 4–12 %) with internal DNA markers 
as described in our earlier publication [15]. The gel was 
stained with indoine blue and divided into three pieces. 
The proteins were reduced with 100  mM dithiotrei-
tol (DTT) in 25 mM NH4HCO3 for 30 min at 56 °C and 
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alkylated with 55  mM iodoacetamide (IAA) in 25  mM 
NH4HCO3 for 30  min at room temperature followed 
by trypsin digestion overnight. Peptides were extracted 
with 0.1  % trifluoroacetic acid (TFA) and 70  % acetoni-
trile/5 % TFA in water, respectively. Extracts were dried 
in a Speedvac and subsequently acidified to 0.1  % TFA. 
The samples were desalted using a ZipTip (C18).
For biomarker discovery, all samples were subject to tan-
dem mass spectrometry. Three injection replicates of each 
fraction (three fractions per sample) were run on an LTQ-
Orbitrap Velos mass spectrometer (Thermo Scientific). For 
each injection replicate, 1.5  µl sample was separated via 
C18 column over the course of a 150  min gradient from 
buffer A (2 % acetonitrile, 98 % H2O, 0.1 % formic acid) to 
buffer B (98  % acetonitrile, 2  % H2O, 0.1  % formic acid). 
The gradient program began with 2  min at 98  % A, fol-
lowed by a 3 min ramp to 95 % A, a 115 min ramp to 60 % 
A, a 15 min ramp to 2 % A, 3 min at 2 % A, 2 min ramp 
to 98  % A, then a 10  min equilibration in 98  % A. MS1 
scans were detected in the FTMS section of the Orbitrap 
Velos in profile mode at a resolution of 30,000 (full width 
of peak at half-maximum at 400 m/z). The ten most abun-
dant parent ions from each MS1 scan were selected for 
fragmentation via collision induced dissociation. Results 
of SEQUEST searches against UniProt human database 
(version April 2013) and all nine runs of each sample were 
combined using Visualize software. Visualize software was 
also used to generate comparison data [16]. The protein 
lists include proteins identified with at least five scans that 
were observed with peptide probability >0.85.
S100A8 expression
S100A8 levels were determined using a S100A8 enzyme-
linked immunoassay kit from MBL International (Des 
Plaines, IL).
Induced pluripotent stem cell induced‑cardiomyocyte 
differentiation
The induced pluripotent stem cell (iPSC) line used in this 
study was a generous gift from Dr. Stephan Duncan. This 
iPSC line was generated from human foreskin fibroblasts 
and previously characterized [17]. The iPSC line was 
maintained on Matrigel (BD Biosciences, San Jose, CA) 
in mTeSR-1 media (Stem Cell Technologies, BC, Canada) 
and differentiated into cardiomyocytes according to pub-
lished protocols [18, 19]. Differentiated cells were main-
tained in cardiomyocyte maintenance media (RPMI/B27; 
Life Technologies, Grand Island, NY). For all experiments, 
35 ± 5 day old contracting cardiomyocytes were used.
Electrophysiology
Action potentials were recorded from the human 
iPSC-derived cardiomyocytes using the current clamp 
configuration of the patch clamp technique, as previously 
described [20, 21]. Briefly, patch pipettes were pulled 
from borosilicate glass capillaries (King Precision Glass, 
Claremont, CA) with a micropipette puller (PC-10; Har-
ishige, Tokyo, Japan) and heat polished using a micro-
forge (MF-830; Narishige). The pipette resistances ranged 
from 3–5 MΩ when filled with the intracellular recording 
solution. This pipette solution contained 60 mM K-gluta-
mate, 50 mM KCL, 10 mM HEPES, 1 mM MgCl2, 11 mM 
EGTA, 1 mM CaCl2, and 5 mM K2-ATP (pH adjusted to 
7.4 with KOH). The extracellular bath solution contained 
132  mM NaCl, 4.8  mM  KCl, 1.2  mM MgCl2, 1.0  mM 
CaCl2, 5 mM dextrose, and 10 mM HEPES (pH adjusted 
7.4 with NaOH). Action potentials were recorded using 
a Multiclamp 700B amplifier and Digidata 1440A inter-
face (Molecular Devices, Sunnyvale, CA). pClamp 10 
software (Molecular Devices) was used for data acquisi-
tion and analysis. Spontaneously beating nodal-, atrial-, 
and ventricular-like cells were characterized based on the 
maximum rate of depolarization (dV/dt), action potential 
duration (APD) at 50 and 90 % repolarization, and maxi-
mum diastolic potential. Recordings were conducted at 
physiological temperature (37  °C). The temperature of 
the recording chamber was controlled via a temperature 
control unit (TC 344B; Warner Instruments, Hamden, 
CT).
Ratiometric Ca2+ microfluorometry
Briefly, human iPSC-derived cardiomyocytes plated on 
coverslips were exposed to Fura-2-AM (5 µM) for 30 min 
at room temperature, washed three times with extracel-
lular bath solution, and given 30 min for de-esterification. 
For Ca2+ microfluorometry, the fluorophore was excited 
alternately with 340 and 380  nm wavelength illumina-
tion and images were acquired at 510 nm through a 20× 
objective. Recordings from each cell were obtained at a 
rate of 3 Hz. After background subtraction, the fluores-
cence ratio R for individual cell was determined as the 
intensity of emission during 340  nm excitation (I340) 
divided by I380, on a pixel-by-pixel basis. Activation-
induced transients were generated by depolarization pro-
duced by microperfusion application of 50 mM KCl [22].
Statistical analysis
Data is presented as either mean ±  SD or as total per-
centage. Continuous variables were compared using the 
Student t test, assuming equal variance and dichotomous 
variables were compared using the Fisher exact test. 
Mass spectrometry measurements between groups were 
compared for either the presence (assigned a number 
value of 1) or absence (assigned a number of value of 0) of 
the protein identified in the sample using non-parametric 
Wilcoxon rank-sum tests without adjusting for multiple 
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testing. Mass spectrometry data analysis was performed 
by the biostatical consulting service at the Medical Col-
lege of Wisconsin.
Results
Clinical and echocardiographic characteristics of the 
discovery cohort
As described in Table 1 the median age of the HFpEF sub-
jects is slightly greater than the control subjects (p = 0.04). 
The HFpEF group had a higher incidence of atrial fibrilla-
tion and cerebral vascular accident/transient ischemia in 
comparison to control subjects. Although not statistically 
significant, HFpEF subjects were more likely to have dia-
betes, coronary heart disease, hyperlipidemia and a distant 
smoking history. A significant number of HFpEF subjects 
were taking beta blockers compared to the control group. 
Echocardiogram studies confirmed the presence of dias-
tolic dysfunction and increased LV pressure in the HFpEF 
group (Table  2). Left atrial volume indices were signifi-
cantly elevated along with an increase in LV wall thickness 
in the HFpEF group compared to control.
Overall description of proteomic findings
Global proteomic experiments were performed using 
21 separate platelet preparations. Combining these 
experiments, a total of 6102 proteins were identified with 
at least five scans with a protein probability of >0.85. The 
HFpEF hospitalized group had a total of 5546 proteins, 
the HFpEF outpatient group had a total of 4854 proteins 
and the control group had a total of 5498 proteins iden-
tified. A total of 4172 proteins were found to be shared 
among all three groups. When comparing two groups, 
321 proteins were identified as being shared amongst 
the outpatient and control group. A total of 361 pro-
teins were found in both the hospitalized and outpatient 
groups and a total of 848 proteins were found in both the 
control and hospitalized groups. The number of unique 
proteins in each group consisted of 165 proteins in the 
HFpEF hospitalized group, 78 proteins in the HFpEF 
outpatient group, and 157 unique proteins in the con-
trol group (Fig. 1). To assess for possible contamination 
from other blood cells, the data set was scanned for the 
presence of CD45 and MHC II chains; proteins that are 
expressed in leukocytes. These proteins were not found 
in the data set; therefore, the contamination from leu-
kocytes was likely to be minimal. However, complement 
C5 and β-2-glycoprotein were identified in the data sets 
denoting some serum contamination was present.
Unique proteins in each study group
The platelet proteome from nine subjects were ana-
lyzed in the HFpEF hospitalized group, five subjects in 
the HFpEF outpatient and seven subjects in the control 
group. The unique proteins identified with a scan count 
of >9 are listed in Table 3. In addition after applying the 
non-parametric Wilcoxon rank-sum test, 37 proteins 
Table 1 Clinical characteristics of subjects
h/o history of; CVA/TIA cerebral vascular accident/transient ischemic attack, Afib 
atrial fibrillation, ACEI/ARB angiotensin converting enzyme inhibitor/angiotensin 
receptor blocker
The p value was calculated using two tailed student t-tests for numerical 
variables and using Chi squared and Fisher’s exact tests for categorical values
Characteristic HFpEF (n = 9) Control (n = 7) p value <0.05
Age, years 75 ± 10 62 ± 13 0.03
Women (%) 75 71 n.s.
Body mass index 33 ± 9 33 ± 10 n.s.
Hypertensive (%) 67 75 n.s.
Hyperlipidemia (%) 67 63 n.s.
Diabetes (%) 56 25 n.s.
Coronary artery  
disease (%)
56 29 n.s.
h/o CVA/TIA (%) 50 0 0.02
h/o Afib (%) 78 0 <0.001
Smoking history (%) 100 29 <0.001
Current smoker (%) 11 14 n.s.
Former smoker (%) 89 14 n.s.
Medications
ACEI/ARB (%) 50 57 n.s




Statin (%) 75 57 n.s.
Diuretic (%) 44 43 n.s.
Table 2 Echocardiographic characteristics of subjects
LA left atrium, LV left ventricle
The p value was calculated using two-tailed student t-tests
Characteristic HFpEF (n = 9) Control (n = 7) p value <0.05
2D Echocardiography
LA volume index,  
ml/m2
49 ± 15 32 ± 7.7 0.018
LV internal diameter,  
cm
4.64 ± 0.37 4.73 ± 0.08 NS
Interventricular sep‑
tum, cm
1.25 ± 0.12 0.92 ± 0.01 0.001
Posterior wall, cm 1.20 ± 0.18 0.88 ± 0.09 0.004
LV mass index, g/m2 112 ± 20 90 ± 45 NS
Ejection fraction,  % 55 ± 6 60 ± 3 NS
Doppler data
E peak, cm/s 86.6 ± 26 68.0 ± 5.8 NS
e′ peak 6.9 ± 1.66 7.7 ± 1.03 NS
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were found to be more prevalent amongst the combined 
HFpEF groups than with the control and 77 proteins were 
identified that were found to be more prevalent amongst 
the control with a p value <0.05. These proteins are listed 
Table 4.
Discovery and validation cohort ELISA confirmation
One particularly interesting finding was the identification 
of S100A8. The m/z ratio graph representing S100A8 is 
shown in Fig. 2. Even though the p value was 0.08, it was 
identified in six out of the nine HFpEF subjects. S100A8 
has not been previously associated with HFpEF but has 
been linked to advanced heart failure [23]. Additionally, 
S100A8 has been found to correlate with traditional car-
diovascular risk factors and the manifestation of cardio-
vascular disease [24, 25]. For these reasons, we decided 
to look more closely at S100A8 to verify its association 
with HFpEF. S100A8 is found in platelets [26, 27] and the 
plasma [25, 28]; because we used the platelet lysates for 
the mass spect analysis, we used the plasma samples for 
quantitative ELISA analysis. Figure 3 shows that plasma 
S100A8 levels are increased symptomatic HFpEF when 
compared to control (MCW cohort). We then validated 
these findings by studying a larger cohort of subjects 
recruited from the Northwestern University HFpEF Pro-
gram. In this larger cohort, we saw a similar increase in 
plasma S100A8 levels in the HFpEF group (Fig. 3; North-
western cohort).
Exogenously applied rS100A8 affects cardiomyocyte 
function in vitro
To ascertain whether S100A8 may play a causal role in 
the HFpEF disease process; we developed a bedside-to-
bench translational system (Fig. 4) to screen for biological 
effects of identified proteins on cardiomyocyte function 
in vitro. We added recombinant S100A8 (800 ng/ml) to 
iPSC-derived cardiomyocytes in  vitro and measured 
action potentials and intracellular Ca2+ concentra-
tions separately. This specific concentration of rS100A8 
was selected as it was the average plasma concentration 
observed in the HFpEF group (Fig. 3).
Action potentials (APs) were recorded in the cur-
rent clamp mode using the patch clamp technique. The 
recordings were acquired from spontaneously beating 
cells. External application of rS100A8 slowed the spon-
taneous pacing within 25  s which suggests the interac-
tion with a membrane receptor. In the example shown 
in Fig.  5a, the spontaneous generation of APs with 
atrial-like properties was slowed in the presence of 
rS100A8. The peak-to-peak AP interval increased from 
1.5 to 2.4  s. This effect was reversible upon washout of 
rS100A8 (results not shown). In a different beating cell 
cluster, the recorded atrial-like APs showed arrhythmo-
genic tendencies characterized by infrequent incidents of 
failed triggering of APs, as shown in Fig. 5b. The rS100A8 
exacerbated this trend by increasing the frequency of 
these failed events. Thus, the electrophysiological pro-
file of these iPSC-derived cardiomyocytes is profoundly 
impacted by rS100A8.
Intracellular Ca2+ concentrations ([Ca2+]i) were meas-
ured using the ratiometric Ca2+ microfluorometry tech-
nique with Fura-2-AM fluorescent dye. The [Ca2+]i were 
monitored in spontaneously beating cells. The sam-
ple trace (Fig.  5c) shows a spontaneous Ca2+ transient 
recording that was interrupted by activity-induced depo-
larization (50 mM K+; duration of application as noted) 
at certain time points (indicated by the red arrows) using 
a microperfusion system. Of particular note is the recov-
ery of the spontaneous Ca2+ transient following each 
depolarizing pulse. In the absence of rS100A8, the recov-
ery was relatively fast. In contrast, the recovery was con-
siderably slower in the presence of rS100A8. Following a 
third depolarizing pulse, recovery was not evident until 
the washout of rS100A8; this observation also suggests 
that rS100A8 effects are mediated through a membrane 
receptor. In summary, rS100A8 adversely affected the 
calcium handling of iPSC-derived cardiomyocytes.
Conclusions
The key finding of this study was that it was possible 
to derive platelet protein data sets specific for HFpEF 
patients. These proof-of-concept findings suggest that 
Fig. 1 Global proteomic analysis of platelets identifies 6102 proteins. 
The Venn diagram displays he results of the analysis of platelet 
proteins from the individual subjects by in‑depth LC–MS/MS. In total, 
6102 proteins were identified with 4172 common among all data 
sets. There were 165, 78, and 157 proteins identified that were unique 
to the HFpEF Symptomatic, HFpEF outpatient and Control groups
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Table 3 List of unique proteins identified in each group with >9 scans total
Protein Accession Description
Present only in HFpEF symptomatic group
 NALP2 Q9NX02 NACHT, LRR and PYD domains‑containing protein
 ZEP3 Q5T1R4 Transcription factor HIVEP3
 MET25 Q8N6Q8 Methyltransferase‑like protein 25
 SCAF8 Q9UPN6 Protein SCAF8
 CC105 Q8IYK2 Coiled‑coil domain‑containing protein 105
 FILA P20930 Filaggrin
 MEG11 A6BM72 Multiple epidermal growth factor‑like domains protein 11
 F19A2 Q8N3H0 Protein FAM19A2
 GRM1 Q13255 Metabotropic glutamate receptor
 YP010 Q96M66 Putative uncharacterized protein FLJ32790
 PSMD4 P55036 26S proteasome non‑ATPase regulatory subunit 4
 PCCA P05165 Propionyl‑CoA carboxylase alpha chain, mitochondrial
 TCPR2 O15040 Tectonin beta‑propeller repeat‑containing protein
 KPRP Q5T749 Keratinocyte proline‑rich protein
 GTPB5 Q9H4K7 GTP‑binding protein 5
 CV031 O95567 Uncharacterized protein C22orf31
 TFB2 M Q9H5Q4 Dimethyladenosine transferase 2, mitochondrial
 SPXN4 Q5MJ08 Sperm protein associated with the nucleus on the X chromosome N4
 PF21A Q96BD5 PHD finger protein 21A
Present only in HFpEF asymptomatic group
 H2A1H Q96KK5 Histone H2A type
 H2A3 Q7L7L0 Histone H2A type 3
 POK7 Q9QC07 HERV‑K_1q23.3 provirus ancestral Pol protein
 CC127 Q96BQ5 Coiled‑coil domain‑containing protein 127
 CC85C A6NKD9 Coiled‑coil domain‑containing protein 85C
 WDR75 Q8IWA0 WD repeat‑containing protein 75
 CXCL3 P19876 C‑X‑C motif chemokine 3
 RGPS1 Q5JS13 Ras‑specific guanine nucleotide‑releasing factor RalGPS1
 CXCL2 P19875 C‑X‑C motif chemokine 2
 CHMP7 Q8WUX9 Charged multivesicular body protein 7
 CK2N2 Q96S95 Calcium/calmodulin‑dependent protein kinase II inhibitor 2
 CHIT1 Q13231 Chitotriosidase‑1
 NOX1 Q9Y5S8 NADPH oxidase 1
 RBY1C P0DJD4 RNA‑binding motif protein, Y chromosome, family 1 member C
 WFDC3 Q8IUB2 WAP four‑disulfide core domain protein 3
 ABCBB O95342 Bile salt export pump
 HHAT Q5VTY9 Protein‑cysteine N‑palmitoyltransferase HHAT
 MID51 Q9NQG6 Mitochondrial dynamic protein MID51
 LMNB1 P20700 Lamin‑B1
Present only in control group
 MY15B Q96JP2 Putative unconventional myosin‑XVB
 CC020 Q8ND61 Uncharacterized protein C3orf20
 MCTS1 Q9ULC4 Malignant T cell‑amplified sequence 1
 KSR1 Q8IVT5 Kinase suppressor of Ras 1
 PRP6 O94906 Pre‑mRNA‑processing factor 6
 DDX59 Q5T1V6 Probable ATP‑dependent RNA helicase DDX59
 AL1A3 P47895 Aldehyde dehydrogenase family 1 member A3
 PCCB P05166 Propionyl‑CoA carboxylase beta chain, mitochondrial
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Table 3 continued
Protein Accession Description
 HNRCL O60812 Heterogeneous nuclear ribonucleoprotein C‑like 1
 BIRC3 Q13489 Baculoviral IAP repeat‑containing protein 3
 NDUF4 Q9P032 NADH dehydrogenase 1 alpha subcomplex assembly factor 4
 MIRO2 Q8IXI1 Mitochondrial Rho GTPase 2
Present in HFpEF symptomatic and HFpEF asymptomatic groups but not control group
 MBD5 Q9P267 Methyl‑CpG‑binding domain protein 5
 RRBP1 Q9P2E9 Ribosome‑binding protein 1
 ZNF79 Q15937 Zinc finger protein 79
 DCNL5 Q9BTE7 DCN1‑like protein 5
 RGS3 P49796 Regulator of G‑protein signaling 3
 TMOD2 Q9NZR1 Tropomodulin‑2
 MYO5B Q9ULV0 Unconventional myosin‑Vb
 SC24D O94855 Protein transport protein Sec24D
 SHIP1 Q92835 Phosphatidylinositol 3,4,5‑trisphosphate 5‑phosphatase 1
 ASIC1 P78348 Acid‑sensing ion channel 1
 DMXL1 Q9Y485 DmX‑like protein 1
 RECQ1 P46063 ATP‑dependent DNA helicase Q1
 LY10L Q9H930 Nuclear body protein SP140‑like protein
 MBNL1 Q9NR56 Muscleblind‑like protein 1
 KCC2B Q13554 Calcium/calmodulin‑dependent protein kinase type II subunit beta
 LIPA3 O75145 Liprin‑alpha‑3
 CD109 Q6YHK3 CD109 antigen
 ZN141 Q15928 Zinc finger protein 141
 YTHD2 Q9Y5A9 YTH domain family protein 2
 PLCD Q9NRZ5 1‑acyl‑sn‑glycerol‑3‑phosphate acyltransferase delta
 KIFA3 Q92845 Kinesin‑associated protein 3
 TRI25 Q14258 E3 ubiquitin/ISG15 ligase TRIM25
 ETUD1 Q7Z2Z2 Elongation factor Tu GTP‑binding domain‑containing protein 1
 CDN1B P46527 Cyclin‑dependent kinase inhibitor 1B
 CO4A4 P53420 Collagen alpha‑4(IV) chain
 TEX35 Q5T0J7 Testis‑expressed sequence 35 protein
 MUC16 Q8WXI7 Mucin‑16
 NPIL2 A6NJ64 NPIP‑like protein LOC729978
 IRF2 P14316 Interferon regulatory factor 2
 MK07 Q13164 Mitogen‑activated protein kinase 7
 APOA P08519 Apolipoprotein(a)
 HIBCH Q6NVY1 3‑hydroxyisobutyryl‑CoA hydrolase, mitochondrial
 USH1C Q9Y6N9 Harmonin
 GOG8O A6NCC3 Golgin subfamily A member 8O
 NADE Q6IA69 Glutamine‑dependent NAD(+) synthetase
 MET17 Q9H7H0 Methyltransferase‑like protein 17, mitochondrial
 PITH1 Q9GZP4 PITH domain‑containing protein 1
 IL1R1 P14778 Interleukin‑1 receptor type 1
 C1GLT Q9NS00 Glycoprotein‑N‑acetylgalactosamine 3‑beta‑galactosyltransferase 1
 OR2L3 Q8NG85 Olfactory receptor 2L3
 KV122 P04430 Ig kappa chain V‑I region BAN
 GG8L2 A6NP81 Golgin subfamily A member 8‑like protein 2
 ZFYV1 Q9HBF4 Zinc finger FYVE domain‑containing protein 1
 CJ076 Q5T2E6 UPF0668 protein C10orf76
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the platelet proteome might provide a useful tool for 
screening for HFpEF-associated biomarkers. Although 
several platelet proteins were identified in HFpEF sub-
jects; their exact connection to HFpEF has yet to be 
determined. Though our data is limited by the small size, 
our discovery cohort has similar characteristics of larger 
HFpEF cohorts reported in the literature [29–31]. By 
combining proteomics with bioactivity assays, we have 
demonstrated that the platelet proteome is an untapped 
resource for determining disease mediators in HFpEF.
The platelet proteome in healthy individuals is 
remarkably stable with only minor differences in pro-
tein expression patterns [32]. Veitinger et  al. suggests 
the difference in platelet proteins between individuals is 
a results of the uptake of plasma proteins by the plate-
let [33]. Inflammation is closely linked with HFpEF [34] 
and considering that platelets are involved in the inflam-
matory process, it is not surprising that our proteom-
ics screen led to the identification of several proteins 
also involved in inflammation. These include serum 
amyloid A (SAA), Lipopolysaccharide binding protein, 
apolipoprotein A1 and S100A8. Two proteins, serum 
amyloid-A (SAA) protein 1 and apolipoprotein A1 were 
increased in the sera of non-human primates after drug-
induced cardiac injury [35]. In addition, increased lev-
els of SAA in serum have been associated with coronary 
heart disease [36], as well as systolic heart failure [37] 
and has been shown to be a predictor of cardiovascular 
outcomes in women [38].
S100A8 is a member of the S100 calcium-binding fam-
ily of proteins, which exhibit increased levels in a number 
of inflammatory states. S100A8 is commonly mentioned 
with its binding partner, S100A9. Even though S100A8 is 
found in the plasma [23], it is known that platelets and 
megakaryocytes might serve as an additional source 
of S100A8 and might contribute to the plasma pool of 
S100A8/A9 in inflammatory diseases and cardiovascular 
events [26, 27, 39].
S100A8 and S100A9 are not normally expressed in car-
diomyocytes [40] although its cardiac expression can be 
induced by endotoxins or angiotensin II [40, 41]. Release 
of S100A8/A9 from cells allows it to act in a paracrine 
or autocrine fashion. These extracellular functions are 
mediated by the toll-like receptor 4 (TLR4) [42, 43] or the 
receptor for advanced glycation end products (RAGE) 
[40, 44, 45]. More recently, CD36 has been identified as a 
receptor [26]. In the mouse, S100A8/A9 signals through 
RAGE to promote inflammation and fibrosis after angio-
tensin II or hypoxic-induced cardiac injury [41, 45].
Increased platelet S100A8 mRNA and plasma protein 
levels were present in patients with acute myocardial 
infarction [39]. Plasma levels of S100A8/A9 predicted 
risk of future myocardial infarction, stroke or death in 
post-menopausal healthy women [25]. Elevated S100A8 
levels have also been found in other inflammatory disor-
ders which are associated with abnormalities of vascular 
and cardiac function, particularly diastolic dysfunction, 
such as diabetes [46–48], end-stage renal disease [49, 
Table 3 continued
Protein Accession Description
 STAB 1 Q9NY15 Stabilin‑1
 EHBP1 Q8NDI1 EH domain‑binding protein 1
 ANR24 Q8TF21 Ankyrin repeat domain‑containing protein 24
 FAHD1 Q6P587 Acylpyruvase FAHD1, mitochondrial
 IWS1 Q96ST2 Protein IWS1 homolog
 THAP2 Q9H0W7 THAP domain‑containing protein 2
 FNIP1 Q8TF40 Folliculin‑interacting protein 1
 STK16 O75716 Serine/threonine‑protein kinase 16
 CXX1 O15255 CAAX box protein 1
 GOG8R I6L899 Golgin subfamily A member 8R
 SRRT Q9BXP5 Serrate RNA effector molecule homolog
 ZN611 Q8N823 Zinc finger protein 611
 MRE11 P49959 Double‑strand break repair protein MRE11A
 LONM P36776 Lon protease homolog, mitochondrial
 GOG8 N F8WBI6 Golgin subfamily A member 8 N
 ALPK2 Q86TB3 Alpha‑protein kinase 2
 EI2BG Q9NR50 Translation initiation factor eIF‑2B subunit gamma
 NBPFL A6NDD8 Neuroblastoma breakpoint family member 21
 ETV7 Q9Y603 Transcription factor ETV7
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Table 4 Proteins preferential to either HFpEF or control groups
Protein Accession Description p value
Proteins preferentially found in HFpEF group
SAA2 P0DJI9 Serum amyloid A‑2 protein 0.0019
SAA1 P0DJI8 Serum amyloid A‑1 protein 0.0019
PHF3 Q92576 PHD finger protein 3 0.0090
RGPD5 Q99666 RANBP2‑like and GRIP domain‑containing protein 5/6 0.0123
RGPD8 O14715 RANBP2‑like and GRIP domain‑containing protein 8 0.0124
YMEL1 Q96TA2 ATP‑dependent zinc metalloprotease YME1L1 0.0256
FHR2 P36980 Complement factor H‑related protein 2 0.0269
RGPD3 A6NKT7 RanBP2‑like and GRIP domain‑containing protein 3 0.0278
CG010 Q9HAC7 CaiB/baiF CoA‑transferase family protein C7orf10 0.0279
RRBP1 Q9P2E9 Ribosome‑binding protein 1 0.0279
ZNF79 Q15937 Zinc finger protein 79 0.0279
DCNL5 Q9BTE7 DCN1‑like protein 5 0.0279
RECQ1 P46063 ATP‑dependent DNA helicase Q1 0.0283
PERQ2 Q6Y7W6 PERQ amino acid‑rich with GYF domain‑containing protein 2 0.0285
MBD5 Q9P267 Methyl‑CpG‑binding domain protein 5 0.0286
GPCP1 Q9NPB8 Glycerophosphocholine phosphodiesterase GPCPD1 0.0286
NOL10 Q9BSC4 Nucleolar protein 10 0.0351
LBP P18428 Lipopolysaccharide‑binding protein 0.0432
AFF1 P51825 AF4/FMR2 family member 1 0.0442
SOX30 O94993 Transcription factor SOX‑30 0.0458
DCP1A Q9NPI6 mRNA‑decapping enzyme 1A 0.0465
AN20B Q5CZ79 Ankyrin repeat domain‑containing protein 20B 0.0468
TCOF Q13428 Treacle protein 0.0479
MEN1 O00255 Menin 0.0486
S10A8 P05109 S100A8 0.0808
Proteins preferentially found in control group
MY15B Q96JP2 Putative unconventional myosin‑XVB 0.0012
ASXL3 Q9C0F0 Putative Polycomb group protein ASXL3 0.0045
CC020 Q9NX02 NACHT, LRR and PYD domains‑containing protein 2 0.0045
TEKT1 Q969V4 Tektin‑1 0.0070
SEP10 Q9P0V9 Septin‑10 OS = Homo sapiens 0.0103
LMNB2 Q03252 Lamin‑B2 OS = Homo sapiens 0.0103
ZN469 Q96JG9 Zinc finger protein 469 0.0146
PARI Q9NWS1 PCNA‑interacting partner 0.0148
NOP2 P46087 Putative ribosomal RNA methyltransferase NOP2 0.0148
FIGL2 A6NMB9 Putative fidgetin‑like protein 2 0.0148
MCTS1 Q9ULC4 Malignant T‑cell‑amplified sequence 1 0.0148
TANC2 Q9HCD6 Protein TANC2 0.0148
HEM0 P22557 5‑aminolevulinate synthase, erythroid‑specific, mitochondrial 0.0148
PRP6 O94906 Pre‑mRNA‑processing factor 6 0.0148
TACC2 O95359 Transforming acidic coiled‑coil‑containing protein 2 0.0200
SMC3 Q9UQE7 Structural maintenance of chromosomes protein 3 0.0261
GTF2I P78347 General transcription factor II‑I 0.0262
CI084 Q5VXU9 Uncharacterized protein 0.0268
CCS O14618 Copper chaperone for superoxide dismutase 0.0294
COX6C P09669 Cytochrome c oxidase subunit 6C 0.0324
INT11 Q5TA45 Integrator complex subunit 11 0.0352
DCLK1 O15075 Serine/threonine‑protein kinase DCLK1 0.0363
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Table 4 continued
Protein Accession Description p value
SSH1 Q8WYL5 Protein phosphatase Slingshot homolog 1 0.0380
PJA1 Q8NG27 E3 ubiquitin‑protein ligase Praja‑1 0.0390
BRK1 Q8WUW1 Protein BRICK1 0.0422
UBP44 Q9H0E7 Ubiquitin carboxyl‑terminal hydrolase 44 0.0422
PLCG2 P16885 1‑phosphatidylinositol 4,5‑bisphosphate phosphodiesterase gamma‑2 0.0428
IGS22 Q8N9C0 Immunoglobulin superfamily member 22 0.0431
RPGFL Q9UHV5 Rap guanine nucleotide exchange factor‑like 1 0.0431
CN070 Q86TU6 Putative uncharacterized protein encoded by LINC00523 0.0431
TRI35 Q9UPQ4 Tripartite motif‑containing protein 35 0.0431
TOPB1 Q92547 DNA topoisomerase 2‑binding protein 1 0.0431
R3HD4 Q96D70 R3H domain‑containing protein 4 0.0431
ABR Q12979 Active breakpoint cluster region‑related protein 0.0431
ZN441 Q8N8Z8 Zinc finger protein 441 0.0431
ZN451 Q9Y4E5 Zinc finger protein 451 0.0431
DCE2 Q05329 Glutamate decarboxylase 2 0.0431
RAB31 Q13636 Ras‑related protein Rab‑31 0.0431
PDE3A Q14432 cGMP‑inhibited 3′, 5′‑cyclic phosphodiesterase A 0.0431
TRPM2 O94759 Transient receptor potential channel subfamily M member 2 0.0431
C163B Q9NR16 Scavenger receptor cysteine‑rich type 1 protein M160 0.0431
CA094 Q6P1W5 Uncharacterized protein C1orf94 0.0431
RSBN1 Q5VWQ0 Round spermatid basic protein 1 0.0431
GRM8 O00222 Metabotropic glutamate receptor 8 0.0431
KLHL7 Q8IXQ5 Kelch‑like protein 7 0.0431
SHAN3 Q9BYB0 SH3 and multiple ankyrin repeat domains protein 3 0.0431
TTI1 O43156 TELO2‑interacting protein 1 homolog 0.0431
FMO4 P31512 Dimethylaniline monooxygenase [N‑oxide‑forming] 4 0.0431
RARB P10826 Retinoic acid receptor beta 0.0431
UTY O14607 Histone demethylase UTY 0.0431
SLK Q9H2G2 STE20‑like serine/threonine‑protein kinase 0.0431
RB39B Q96DA2 Ras‑related protein Rab‑39B 0.0435
RB43L A6NDJ8 Putative Rab‑43‑like protein 0.0435
RAB4B P61018 Ras‑related protein Rab‑4B 0.0435
RAB12 Q6IQ22 Ras‑related protein Rab‑12 0.0435
RAB43 Q86YS6 Ras‑related protein Rab‑43 0.0435
RAB30 Q15771 Ras‑related protein Rab‑30 0.0435
GRM7 Q14831 Metabotropic glutamate receptor 7 0.0435
ZNF67 Q15940 Putative zinc finger protein 726P1 0.0435
FAKD5 Q7L8L6 FAST kinase domain‑containing protein 5 0.0435
ZNF98 A6NK75 Zinc finger protein 98 0.0435
MFSD9 Q8NBP5 Major facilitator superfamily domain‑containing protein 9 0.0435
RECK O95980 Reversion‑inducing cysteine‑rich protein with Kazal motifs 0.0435
AL1A3 P47895 Aldehyde dehydrogenase family 1 member A3 0.0435
VP37C A5D8V6 Vacuolar protein sorting‑associated protein 37C 0.0435
ZN492 Q9P255 Zinc finger protein 492 0.0435
VPS29 Q9UBQ0 Vacuolar protein sorting‑associated protein 29 0.0435
HNRCL O60812 Heterogeneous nuclear ribonucleoprotein C‑like 1 0.0435
DHRS7 Q9Y394 Dehydrogenase/reductase SDR family member 7 0.0452
BRD8 Q9H0E9 Bromodomain‑containing protein 8 0.0455
IF2P O60841 Eukaryotic translation initiation factor 5B 0.0455
Page 11 of 15Raphael et al. J Transl Med  (2016) 14:18 
50], and inflammatory bowel disease [51, 52]. This is the 
first association of S100A8 with HFpEF, yet its role in 
the disease process still needs be elucidated. S100A8 has 
immediate effects on the electrophysiological and Ca2+ 
handling profiles of human induced cardiomyocytes 
suggesting that S100A8 is acting through a membrane 
receptor. S100A8 interaction with RAGE affects cal-
cium flux in neonatal rat ventricular cardiomyocytes 
and HL-1 cardiomyocytes [40, 53]. The adverse effects 
on the electrophysiological and Ca2+ handling profiles 
resulting from S100A8 treatment of human induced 
cardiomyocytes; validates our bedside-to-bench trans-
lational screen as an approach to identify bioactive pro-
teins that may contribute to the disease mechanisms in 
HFpEF.
We also considered the possibility that subjects pro-
gress to HFpEF through loss of cardioprotective proteins. 
Therefore, we searched amongst our control group and 
were able to identify four proteins that could potentially 
have protective qualities against the development of 
heart failure. Cyclic nucleotide phosphodiesterase 3A1 
(PDE3A) regulates β-adrenergic signaling to effect physi-
ological cardiac performance. Furthermore, PDE3A pro-
tects the heart against angiotensin II-induced cardiac 
remodeling in mice [54]. Copper Chaperone for Super-
oxide Dismutase (CCS) plays a role in copper delivery 
to tissues; disturbances in copper homeostasis mediates 
cardiomyopathy [55]. Zinc finger protein 451 a nega-
tive regulator of TGF-beta signaling [56]. The transient 
receptor potential cation channel subfamily M member 2 
Table 4 continued
Protein Accession Description p value
GDPD3 Q7L5L3 Glycerophosphodiesterase domain‑containing protein 3 0.0456
SYSC P49591 Serine–tRNA ligase, cytoplasmic 0.0465
NEK9 Q8TD19 Serine/threonine‑protein kinase Nek9 0.0473
p values are calculated based on the non-parametric Wilcoxon rank-sum tests
Fig. 2 Representative MS/MS scan for S100A8 peptide sequence ALNSIIDVYHK. Raw m/z spectral images with peak assignments and b and y ion 
lists along with a representation of peptide sequencing by tandem mass spectrometry
Fig. 3 Plasma levels of S100A8 in control vs. HFpEF groups. a S100A8 
is found in increased levels in the plasma of subjects with HFpEF vs. 
control subjects as detected by ELISA. The MCW columns include the 
control (n = 7) and HFpEF (n = 9) from the discovery cohort and the 
NWU colums include the control (n = 18) and HFpEF (n = 25) sam‑
ples from the validation cohort. *p < 0.006 vs MCW Control. #p < 0. 
002 vs NWU Control
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(TRPM2) protein limits oxidative stress injury and damp-
ens the inflammatory response [57].
The present study must be interpreted within the 
context of its limitations. First of all, this was a discov-
ery effort and not designed as a quantitative proteomic 
analysis. Therefore, we cannot determine if specific pro-
teins are up- or down-regulated. In addition, it is unlikely 
that one protein is responsible for a complex disease as 
HFpEF, but our findings offer new perspectives regard-
ing HFpEF and further confirmation of the platelet pro-
teins identified in this study will need to be validated in 
a larger cohort. In addition, combining proteomics with 
functional bioactivity assessments may be a strategy to 
complement and strengthen the search for biomarkers by 
combining protein identified with biological activity in a 
relevant in vitro model system.
In conclusion, from the discovery set in HFpEF 
patients, we derived a panel of platelet proteins that may 
be specific for HFpEF. Furthermore, this set distinguished 
a set of platelet proteins which are consistent in HFpEF 
subjects whether they are decompensated and hospital-
ized or compensated after discharge. We further estab-
lished a bedside-to-bench translational system that can 
be utilized as a secondary screen to ascertain whether the 
biomarkers may be an associated finding or causal to the 
disease process.
Fig. 4 Overview of primary and secondary screening methods to identify potential mediators of HFpEF. a Platelet proteomes were subject to mass 
spectral analysis and novel proteins were identified. b Human cardiomyocytes derived from induced pluripotent stem cells were used to determine 
whether proteins that were identified in a had direct effects on cardiomyocytes function in vitro. Purified recombinant protein S100A8 was tested in 
this assay
(See figure on next page.) 
Fig. 5 S100A8‑mediated effects on human iPSC‑derived cardiomyocytes. a Shows example action potentials recorded from rS100A8 treated iPSC 
derived human cardiomyocytes. The addition of rS100A8 to the buffer extended the period between action potentials. This period is phase 4; the 
diastolic membrane potential between action potentials. b rS100A8 exacerbates the arrhythmic tendencies of human cardiomyocytes. c Spontane‑
ous Ca2+ transients recorded from human cardiomyocytes treated with rS100A8 as indicated by the blue line. rS100A8 significantly delayed the 
recovery of depolarization. Wash out of rS100A8 reversed these effects
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